Kiora Pharmaceuticals annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kiora Pharmaceuticals Free Cash Flow (FCF) History (KPRX)
Kiora Pharmaceuticals reported −$10.1M in free cash flow for fiscal 2025, a decrease of $18.6M from the previous fiscal year.
View full Kiora Pharmaceuticals company overviewKiora Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$10.1M | −$18.6M | — | — |
| 2024 | 2024-12-31 | $8.6M | $18.1M | — | +53.39% |
| 2023 | 2023-12-31 | −$9.6M | $871,182 | — | — |
| 2022 | 2022-12-31 | −$10.4M | $311,122 | — | — |
| 2021 | 2021-12-31 | −$10.7M | −$3.4M | — | — |
| 2020 | 2020-12-31 | −$7.3M | $816,587 | — | −60844.56% |
| 2019 | 2019-12-31 | −$8.2M | $2.7M | — | −303.57% |
| 2018 | 2018-12-31 | −$10.9M | −$4.4M | — | −657.45% |
| 2017 | 2017-12-31 | −$6.5M | $1.9M | — | −1596.38% |
| 2016 | 2016-12-31 | −$8.4M | — | — | −1257.09% |
Kiora Pharmaceuticals quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q3.23
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.9M | $1.9M | — | — |
| Q1 2026 | 2026-03-31 | −$3.2M | −$462,151 | — | — |
| Q4 2025 | 2025-12-31 | −$2.3M | −$3.2M | — | — |
| Q3 2025 | 2025-09-30 | −$1.3M | $1.2M | — | — |
| Q2 2025 | 2025-06-30 | −$3.8M | −$915,961 | — | — |
| Q1 2025 | 2025-03-31 | −$2.7M | −$434,092 | — | — |
| Q3 2024 | 2024-09-30 | $920,057 | $3.8M | — | — |
| Q3 2023 | 2023-09-30 | −$2.5M | $107,073 | — | — |
| Q4 2021 | 2021-12-31 | −$2.9M | — | — | — |
| Q3 2021 | 2021-09-30 | −$2.3M | — | — | — |
| Q2 2021 | 2021-06-30 | −$2.9M | — | — | — |
| Q1 2021 | 2021-03-31 | −$2.6M | — | — | — |
Kiora Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$7.3M to −$10.1M, a net decrease of $2.7M. Kiora Pharmaceuticals's latest reported quarter, Q2 2026, generated −$1.9M in free cash flow, an increase of $1.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Kiora Pharmaceuticals filings at SEC.gov ↗